Pharma
Icon plans yearly $500m M&A spree on foot of bumper results
Dublin-headquartered company posted full-year revenues of more than $8.1 billion for 2023, which was up 5 per cent on the previous year
Icon plc, the Dublin-headquartered contract research giant, is planning to spend up to $500 million (€462 million) a year on acquisitions to grow the business, its chief financial officer has said.
The company, which is headquartered in Dublin but listed on the Nasdaq stock exchange in New York, posted a 15 per cent increase in full-year earnings (Ebitda) to just under $1.7 billion, as margins widened to a very strong 21 per cent.
Brendan Brennan, ...
